Alterity Therapeutics (NASDAQ:ATHE) Earns Buy Rating from Analysts at Maxim Group

Maxim Group began coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $8.00 target price on the stock.

Alterity Therapeutics Stock Performance

Shares of NASDAQ ATHE opened at $2.40 on Thursday. The stock’s fifty day moving average is $1.36 and its 200 day moving average is $1.50. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $3.25.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.